MRNA stock clocks best day in over two months on early-stage hantavirus vaccine research

・Bloomberg reported on Friday that Moderna’s hantavirus research is “early-stage and ongoing” and began well before the cruise-ship cluster was identified.・No hantavirus vaccine is currently approved anywhere in the world, and human clinical trials for Moderna’s candidates have not yet begun.・Moderna’s vaccine sales have undergone a dramatic post-pandemic decline.Shares of Moderna Inc. (MRNA) closed 12% higher on Friday, clocking its best day in over two months, after the company confirmed it has been pursuing early-stage research into mRNA-based vaccines against hantaviruses.Moderna’s ongoing hantavirus efforts, reported by Bloomberg, coincide with heightened public attention on a rare outbreak linked to the Dutch-flagged...